Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Novel Bacteriophage Infecting Multi-Drug- and Extended-Drug-Resistant Pseudomonas aeruginosa Strains

  • Santamaría-Corral, Guillermo
  • Pagán, Israel
  • Aguilera-Correa, John Jairo
  • Esteban, Jaime
  • García-Quintanilla, Meritxell
22 Pág., The prevalence of carbapenem-resistant P. aeruginosa has dramatically increased over the last decade, and antibiotics alone are not enough to eradicate infections caused by this opportunistic pathogen. Phage therapy is a fresh treatment that can be administered under compassionate use, particularly against chronic cases. However, it is necessary to thoroughly characterize the virus before therapeutic application. Our work describes the discovery of the novel sequenced bacteriophage, vB_PaeP-F1Pa, containing an integrase, performs a phylogenetical analysis, describes its stability at a physiological pH and temperature, latent period (40 min), and burst size (394 ± 166 particles per bacterial cell), and demonstrates its ability to infect MDR and XDR P. aeruginosa strains. Moreover, this novel bacteriophage was able to inhibit the growth of bacteria inside preformed biofilms. The present study offers a road map to analyze essential areas for successful phage therapy against MDR and XDR P. aeruginosa infections, and shows that a phage containing an integrase is also able to show good in vitro results, indicating that it is very important to perform a genomic analysis before any clinical use, in order to prevent adverse effects in patients., This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. MG-Q is supported by the Subprograma Miguel Servet from the Ministerio de Ciencia e Innovación of Spain (CP19/00104), Instituto de Salud Carlos III (Plan Estatal de I+D+i 2017–2020), and co-funded by the European Social Fund “Investing in your future”. GS-C was supported by the Programa Operativo de Empleo Juvenil and Iniciativa de Empleo Juvenil (YEI) from the Consejería de Ciencia, Universidades e Innovación from Comunidad de Madrid and the European Union, Fondo Social Europeo: “El FSE invierte en tu futuro”. IP was supported by Ministerio de Ciencia e Innovación (Proyectos de Transición Ecológica y Digital, TED2021-130793B-I00)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

P3MA: A Promising Mycobacteriophage Infecting Mycobacterium abscessus

  • Broncano-Lavado, Antonio
  • Aguilera-Correa, John Jairo
  • Roquet-Banères, Françoise
  • Kremer, Laurent
  • Mediero, Aránzazu
  • Seoane-Blanco, Mateo
  • van Raaij, Mark J.
  • Pagán, Israel
  • Esteban, Jaime
  • García-Quintanilla, Meritxell
This article belongs to the Special Issue Bacteriophage Therapy a Renaissance Weapon Recent Developments and Application, 2nd Edition., [Background/Objectives:] Mycobacterium abscessus is an opportunistic pathogen causing infections mainly in patients with immunosuppression and chronic pulmonary pathologies. Extended treatment periods are needed to tackle this pathogen, bacterial eradication is rare, and recurrence can take place with time. New alternative treatments are being investigated, such as bacteriophage therapy. This work describes the characterization of the mycobacteriophage P3MA, showing its ability to infect clinical and standard M. abscessus strains., [Methods:] Phylogenetic analysis, electron microscopy, growth curves, biofilm assays, checkerboard, and granuloma-like medium studies were performed., [Results:] P3MA inhibited the growth of clinical samples in both planktonic and biofilm states as well as in a granuloma-like model. The study of the interaction with antibiotics revealed that P3MA exhibited an antagonistic effect combined with clarithromycin, indifference with amikacin, and synergy with imipenem., [Conclusions:] All these results suggest that, after genetic engineering, P3MA could be a promising candidate for phage therapy in combination with imipenem, including lung infections., This research was funded by CIBERINFEC-CIBER de Enfermedaes Infecciosas (CB21/13/00043) and by Vaincre la Mucoviscidose (RF20230503223) and the Association Gregory Lemarchal. M.J.v.R. was supported by grant PID2021–125597NB-I00 financed by MCIN/AEI/10.13039/501100011033 and the European Union Next Generation EU/PRTR and FEDER. M.G.-Q. was supported by the Subprograma Miguel Servet from the Ministerio de Ciencia e Innovación of Spain (CP19/00104), Instituto de Salud Carlos III (Plan Estatal de I + D+i 2017–2020), and co-funded by the European Social Fund “Investing in your future”. I.P. was supported by Ministerio de Ciencia e Innovación (Proyectos de Transición Ecológica y Digital, TED2021-130793B-I00)., Peer reviewed